Osimertinib

Open Access
Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH)
Lisha Shen, Dongqing Lv, Ke-Jing Tang, Jun Zhao, Dan Zhu, Yanqiu Zhao, Ke Wang, Yan Wang, Zhigang Cai, Ligang Xing, Ke Xie, Jiuwei Cui, Lin Mu, Chao Cao, Liren Ding, Peifeng Chen, Jun Liang, Yongmin Ding, Liqin Lu, Jiliang Zhang, Xinmin Yu, Li Chen, Jing Zheng, Jianya Zhou and Jianying Zhou

Cancer Biology & Medicine May 2026, 20250566; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0566
Open Access
Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages
Yuan Li, Yanping Chen, Yuan Meng, Meng Shen, Fan Yang and Xiubao Ren

Cancer Biology & Medicine December 2024, 21 (12) 1156-1170; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0269

Main menu